glp-1 drug market news today Agonists Weight Loss Drugs Report, 2025-2030 The Multi-Sector Impacts of GLP-1RA

Can patients buy or use retatrutide now

Enteric dysbiosis-linked gut barrier disruption triggers early renal injury induced by chronic high salt feeding in mice

Because SIBO testing is uncommon in the general population, increased testing among GLP-1 users can make it appear that cases are rising, when in reality we are simply increasing testing and therefore finding more cases

Phentermine weight loss data In clinical studies, phentermine produces an average weight loss of 5% to 10% of body weight over 12 weeks to 6 months

2023A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy (available at: 10.1111/dom.15875) [DOI] [PubMed] [Google Scholar] Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Moller DV, Treppendahl MB, Verma S, et al

J., Xia J., Liu J., Mirabella V., Pang Z